ALZNAlzamend Neuro Inc
The schedule
- Wed11Nov
Q3 results will anchor on runway and clinical progress from $0.90, with a $1.35 upside against a $0.65 adverse fallback.
- Mon16Nov
End-of-year pipeline update projecting an explosive binary move from $0.65 to either $1.45 on positive trial advancement or $0.40 on clinical setbacks.
- Tue9Feb
Full-year results measuring fundamental stabilization at $1.45, testing a $1.95 target on pipeline execution versus a $0.95 retracement floor.
- Mon10May
Q1 2027 earnings evaluating renewed cash burn from $1.95, mapping a $2.45 continuation target against a $1.25 adverse reset.
Past
- Wed30Sep
Actual outcome: Bear · $1.36 at outcome
ALZN experienced a sharp decline due to disappointing clinical trial results, which raised concerns about the efficacy of its key drug candidates. The move suggests the data may have fallen short of expectations, potentially impacting the company's development timeline and investor sentiment. The negative outcome likely triggered a reassessment of the stock's future prospects. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-09: -36.1% from 2026-09-24 (~2.2σ). Target date 2026-10-07 reached; move through 2026-10-09 observed.
ALZN experienced a sharp decline due to disappointing clinical trial results, which raised concerns about the efficacy of its key drug candidates. The move suggests the data may have fallen short of expectations, potentially impacting the company's development timeline and investor sentiment. The negative outcome likely triggered a reassessment of the stock's future prospects. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-09: -36.1% from 2026-09-24 (~2.2σ). Target date 2026-10-07 reached; move through 2026-10-09 observed.
- Tue15Sep
Expected near-term resolution of critical liquidity constraints, evaluating ALZN from its $1.55 base with a bearish lean toward highly dilutive financing ($0.90 fallback).
